Skip to main content
Erschienen in: Current Oncology Reports 5/2012

01.10.2012 | Lymphomas (PA Hamlin, Section Editor)

B-Cell Receptor Pathobiology and Targeting in NHL

verfasst von: Ines M. Macias-Perez, Ian W. Flinn

Erschienen in: Current Oncology Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

B-cell receptor signaling plays varied and critical roles in B-cell development, homeostasis and disease. The key players of the pathway and its many signaling modulators have been identified as well as some of the mechanisms by which the pathway is regulated. With the increased incidence of non-Hodgkin’s lymphoma in recent years, there is a clear clinical need for novel agents to offer new options in resistant disease to potentially improve outcomes in curative settings. With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton’s tyrosine kinase, and phosphatidylinositol 3-kinase. This review will emphasize contemporary and salient findings on novel agents targeting the B-cell receptor signaling pathway for the treatment of non-Hodgkin’s lymphoma.
Literatur
1.
Zurück zum Zitat American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2.
Zurück zum Zitat Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin Lymphoma reveal syk as an important therapeutic target. Blood. 2009;113:2508–16.PubMedCrossRef Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin Lymphoma reveal syk as an important therapeutic target. Blood. 2009;113:2508–16.PubMedCrossRef
4.
Zurück zum Zitat Ysebaert L, Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011;20:1167–74.PubMedCrossRef Ysebaert L, Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011;20:1167–74.PubMedCrossRef
5.
Zurück zum Zitat Jumaa H, Hendriks RW, Reth M. B-cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415–45.PubMedCrossRef Jumaa H, Hendriks RW, Reth M. B-cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415–45.PubMedCrossRef
6.
Zurück zum Zitat Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104:1115–21.PubMedCrossRef Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104:1115–21.PubMedCrossRef
7.
Zurück zum Zitat Hombach J, Tsubata T, Leclercq L, et al. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature. 1990;343:760–2.PubMedCrossRef Hombach J, Tsubata T, Leclercq L, et al. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature. 1990;343:760–2.PubMedCrossRef
8.
Zurück zum Zitat Kraus M, Pao LI, Reichlin A, et al. Interference with immunoglobulin (Ig)α immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an igbeta cytoplasmic tail. J Exp Med. 2001;194:455–69.PubMedCrossRef Kraus M, Pao LI, Reichlin A, et al. Interference with immunoglobulin (Ig)α immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an igbeta cytoplasmic tail. J Exp Med. 2001;194:455–69.PubMedCrossRef
9.
Zurück zum Zitat Bannish G, Fuentes-Panana EM, Cambier JC, et al. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001;194:1583–96.PubMedCrossRef Bannish G, Fuentes-Panana EM, Cambier JC, et al. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001;194:1583–96.PubMedCrossRef
10.
Zurück zum Zitat Reichlin A, Hu Y, Meffre E, et al. B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med. 2001;193:13–23.PubMedCrossRef Reichlin A, Hu Y, Meffre E, et al. B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med. 2001;193:13–23.PubMedCrossRef
11.
Zurück zum Zitat Clark MR, Tanaka A, Powers SE, et al. Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of energy. Mol Immunol. 2010;48:1281–6.PubMedCrossRef Clark MR, Tanaka A, Powers SE, et al. Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of energy. Mol Immunol. 2010;48:1281–6.PubMedCrossRef
12.
Zurück zum Zitat • Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302. Syk is essential to couple the BCR to distal signal transduction elements.PubMedCrossRef • Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302. Syk is essential to couple the BCR to distal signal transduction elements.PubMedCrossRef
13.
Zurück zum Zitat • Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303–6. Syk has a critical role in maintaining vascular integrity, promoting differentiation and clonal expansion of B-lineage cells.PubMedCrossRef • Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303–6. Syk has a critical role in maintaining vascular integrity, promoting differentiation and clonal expansion of B-lineage cells.PubMedCrossRef
14.
Zurück zum Zitat Khan WN, Sideras P, Rosen FS, et al. The role of bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;764:27–38.PubMedCrossRef Khan WN, Sideras P, Rosen FS, et al. The role of bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;764:27–38.PubMedCrossRef
15.
Zurück zum Zitat Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 1995;3:549–60.PubMedCrossRef Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 1995;3:549–60.PubMedCrossRef
16.
Zurück zum Zitat Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/itam positive feedback loop. Mol Cell. 2002;10:1057–69.PubMedCrossRef Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/itam positive feedback loop. Mol Cell. 2002;10:1057–69.PubMedCrossRef
17.
Zurück zum Zitat Cornall RJ, Goodnow CC, Cyster JG. Regulation of B cell antigen receptor signaling by the lyn/cd22/shp1 pathway. Curr Top Microbiol Immunol. 1999;244:57–68.PubMedCrossRef Cornall RJ, Goodnow CC, Cyster JG. Regulation of B cell antigen receptor signaling by the lyn/cd22/shp1 pathway. Curr Top Microbiol Immunol. 1999;244:57–68.PubMedCrossRef
18.
Zurück zum Zitat • Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61. A single conserved residue within the amino terminal unique region of Btk was mutated and found to interfere with normal B cell signaling demonstrating the importance of Btk protein interaction, a rationale for targeting Btk in B-cell malignancies.PubMedCrossRef • Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61. A single conserved residue within the amino terminal unique region of Btk was mutated and found to interfere with normal B cell signaling demonstrating the importance of Btk protein interaction, a rationale for targeting Btk in B-cell malignancies.PubMedCrossRef
19.
Zurück zum Zitat Takata M, Kurosaki T. A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma. J Exp Med. 1996;184:31–40.PubMedCrossRef Takata M, Kurosaki T. A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma. J Exp Med. 1996;184:31–40.PubMedCrossRef
20.
Zurück zum Zitat Ishiai M, Kurosaki M, Pappu R, et al. BLNK required for coupling Syk to PLC gamma 2 and rac1-jnk in B cells. Immunity. 1999;10:117–25.PubMedCrossRef Ishiai M, Kurosaki M, Pappu R, et al. BLNK required for coupling Syk to PLC gamma 2 and rac1-jnk in B cells. Immunity. 1999;10:117–25.PubMedCrossRef
21.
Zurück zum Zitat Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12:1–5.PubMedCrossRef Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12:1–5.PubMedCrossRef
22.
Zurück zum Zitat Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls NFkB activation in B cells through selective regulation of the IkB kinase alpha. J Exp Med. 2002;195:1647–52.PubMedCrossRef Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls NFkB activation in B cells through selective regulation of the IkB kinase alpha. J Exp Med. 2002;195:1647–52.PubMedCrossRef
23.
Zurück zum Zitat Argyriou P, Economopoulou P, Sotirios P. The role of mTOR inhibitors for the treatment of B-cell lymphomas. Adv Hematol. 2012;2012:435342.PubMed Argyriou P, Economopoulou P, Sotirios P. The role of mTOR inhibitors for the treatment of B-cell lymphomas. Adv Hematol. 2012;2012:435342.PubMed
24.
Zurück zum Zitat Leseux L, Hamdi SM, Saati TA, et al. Syk-dependent motor activation in follicular lymphoma cells. Blood. 2006;108:4156–62.PubMedCrossRef Leseux L, Hamdi SM, Saati TA, et al. Syk-dependent motor activation in follicular lymphoma cells. Blood. 2006;108:4156–62.PubMedCrossRef
25.
Zurück zum Zitat Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369–78.PubMed Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369–78.PubMed
26.
Zurück zum Zitat •• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11. By gene-expression profiling, tumor, and normal cell analyses, identified two distinct subtypes, an activated B cell-like DLBCL known as ABC subtype, and a germinal centre B-cell DLBCL, patients of which had a significantly better overall survival compared with the ABC genetic signature.PubMedCrossRef •• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11. By gene-expression profiling, tumor, and normal cell analyses, identified two distinct subtypes, an activated B cell-like DLBCL known as ABC subtype, and a germinal centre B-cell DLBCL, patients of which had a significantly better overall survival compared with the ABC genetic signature.PubMedCrossRef
27.
Zurück zum Zitat Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008;22:1755–66.PubMedCrossRef Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008;22:1755–66.PubMedCrossRef
28.
Zurück zum Zitat • Chen L, Monti S, Juszczynski P, et al. SyK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7. Using DLBCL cell lines and primary tumors the important role of Syk in driving survival signals in DLBCL is demonstrated and as a potential target using fostamatinib, a Syk inhibitor.PubMedCrossRef • Chen L, Monti S, Juszczynski P, et al. SyK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7. Using DLBCL cell lines and primary tumors the important role of Syk in driving survival signals in DLBCL is demonstrated and as a potential target using fostamatinib, a Syk inhibitor.PubMedCrossRef
29.
Zurück zum Zitat Rinaldi A, Kwee I, Taborelli M, et al. Geneomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.PubMedCrossRef Rinaldi A, Kwee I, Taborelli M, et al. Geneomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.PubMedCrossRef
30.
Zurück zum Zitat Friedberg J, Sharman J, Schaefer-Cutillo J, et al. Fostamatinib disodium, an oral inhibitor of Syk, is well tolerated and has significant clinical activity in diffuse large B-cell lymphoma and chronic lymphocytic leukaemia. Blood. 2008;112:Abstract 3. Friedberg J, Sharman J, Schaefer-Cutillo J, et al. Fostamatinib disodium, an oral inhibitor of Syk, is well tolerated and has significant clinical activity in diffuse large B-cell lymphoma and chronic lymphocytic leukaemia. Blood. 2008;112:Abstract 3.
31.
Zurück zum Zitat Pollyea DA, Smith S, Fowler N, et al. A phase I dose escalation study of the Btk inhibitor pci-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [Abstract]. Blood. 2009;114:3713. Pollyea DA, Smith S, Fowler N, et al. A phase I dose escalation study of the Btk inhibitor pci-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [Abstract]. Blood. 2009;114:3713.
32.
Zurück zum Zitat Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. PNAS. 2010;107:13075–80.PubMedCrossRef Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. PNAS. 2010;107:13075–80.PubMedCrossRef
33.
Zurück zum Zitat Walsh KJ, Fan S, Patel A, et al. PI3K inhibitors inhibit lymphoma growth by downregulation of MYC-dependent proliferation. Blood. 2011;114:1697. Walsh KJ, Fan S, Patel A, et al. PI3K inhibitors inhibit lymphoma growth by downregulation of MYC-dependent proliferation. Blood. 2011;114:1697.
34.
Zurück zum Zitat Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMedCrossRef Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMedCrossRef
35.
Zurück zum Zitat Vogt PK, Kang S, Elsliger MA, et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32:342–9.PubMedCrossRef Vogt PK, Kang S, Elsliger MA, et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32:342–9.PubMedCrossRef
36.
Zurück zum Zitat Abubaker J, Bavi PP, Al-harbi S, et al. PIK3CA mutations are mutually exclusive with pten loss in diffuse large B-cell lymphoma. Leukemia. 2007;21:2368–70.PubMedCrossRef Abubaker J, Bavi PP, Al-harbi S, et al. PIK3CA mutations are mutually exclusive with pten loss in diffuse large B-cell lymphoma. Leukemia. 2007;21:2368–70.PubMedCrossRef
37.
Zurück zum Zitat Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.PubMedCrossRef Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.PubMedCrossRef
38.
Zurück zum Zitat Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase (PIK3) delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition. 2010; Orlando, Florida. [Abstract 55]. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase (PIK3) delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition. 2010; Orlando, Florida. [Abstract 55].
39.
Zurück zum Zitat • Lannutti BJ, Meadows SA, Kashishian A, et al. CAL-101, an oral p110δ selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B cell malignancies inhibits PI3K signaling, cellular viability and protective signals of the microenvironment. Blood. 2009;114:286. These data demonstrate the important of PI3K isoform-δ in regulating BCR signaling in malignant B-cells as well as the microenvironment thereby providing the rationale for the clinical development of isoform-δ inhibitors of PI3K alone or in combination for patients with hematologic malignancies. • Lannutti BJ, Meadows SA, Kashishian A, et al. CAL-101, an oral p110δ selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B cell malignancies inhibits PI3K signaling, cellular viability and protective signals of the microenvironment. Blood. 2009;114:286. These data demonstrate the important of PI3K isoform-δ in regulating BCR signaling in malignant B-cells as well as the microenvironment thereby providing the rationale for the clinical development of isoform-δ inhibitors of PI3K alone or in combination for patients with hematologic malignancies.
40.
Zurück zum Zitat Friedberg J, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.PubMedCrossRef Friedberg J, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.PubMedCrossRef
41.
Zurück zum Zitat Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:6631. Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:6631.
42.
Zurück zum Zitat Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2010;116:1777. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2010;116:1777.
43.
Zurück zum Zitat Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Oxf J. 2006;17:1418–12. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Oxf J. 2006;17:1418–12.
44.
45.
Zurück zum Zitat O’Brien S, Burger JA, Blum K, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase IB/II study. Blood. 2011;118:983. O’Brien S, Burger JA, Blum K, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase IB/II study. Blood. 2011;118:983.
46.
Zurück zum Zitat Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood. 2011;118:442. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood. 2011;118:442.
47.
Zurück zum Zitat Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients PTS): interim results of a phase Ib/II study. J Clin Oncol. 2012;30:6507. Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients PTS): interim results of a phase Ib/II study. J Clin Oncol. 2012;30:6507.
48.
Zurück zum Zitat Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118:3525–7.PubMedCrossRef Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118:3525–7.PubMedCrossRef
49.
Zurück zum Zitat Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2011;118:1787. Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2011;118:1787.
Metadaten
Titel
B-Cell Receptor Pathobiology and Targeting in NHL
verfasst von
Ines M. Macias-Perez
Ian W. Flinn
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 5/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0254-8

Weitere Artikel der Ausgabe 5/2012

Current Oncology Reports 5/2012 Zur Ausgabe

Lymphomas (PA Hamlin, Section Editor)

Novel Agents in Hodgkin Lymphoma

Leukemia (A Aguayo, Section Editor)

Chronic Myeloid Leukemia: State of the Art in 2012

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.